Winst gevend schreef op 19 april 2022 17:23:
[...]
Charlotte Cunningham-Rundles, M.D., Ph.D., David S. Gottesman Professor of Immunology at
the Mount Sinai School of Medicine in New York, said:
“It is great news that leniolisib has achieved such positive results in this Phase III study in APDS.
It is extremely encouraging to see that this medication is capable of targeting the cause of this
difficult disease, both improving care and reducing patients’ symptoms. Progress toward a
treatment that is tailor-made for our patients with APDS is a milestone we have long awaited.”
Anders nog iets erbij?